The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
- PMID: 17461796
- DOI: 10.1111/j.1600-0854.2007.00562.x
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Erratum in
- Traffic. 2007 Jul;8(7):950
Abstract
Mutations in the proprotein convertase PCSK9 gene are associated with autosomal dominant familial hyper- or hypocholesterolemia. These phenotypes are caused by a gain or loss of function of proprotein convertase subtilisin kexin 9 (PCSK9) to elicit the degradation of the low-density lipoprotein receptor (LDLR) protein. Herein, we asked whether the subcellular localization of wild-type PCSK9 or mutants of PCSK9 and the LDLR would provide insight into the mechanism of PCSK9-dependent LDLR degradation. We show that the LDLR is the dominant partner in regulating the cellular trafficking of PCSK9. In cells lacking the LDLR, PCSK9 localized in the endoplasmic reticulum (ER). In cells expressing the LDLR, PCSK9 sorted to post-ER compartments (i.e. endosomes in cell lines and Golgi apparatus in primary hepatocytes), where it colocalized with the LDLR. In cell lines, PCSK9 also colocalized with the LDLR at the cell surface, requiring the presence of the C-terminal Cys/His-rich domain of PCSK9. We provide evidence that PCSK9 promotes the degradation of the LDLR by an endocytic mechanism, as small interfering RNA-mediated knockdown of the clathrin heavy chain reduced the functional activity of PCSK9. We also compared the subcellular localization of natural mutants of PCSK9 with that of the wild-type enzyme in human hepatic (HuH7) cells. Whereas the mutants associated with hypercholesterolemia (S127R, F216L and R218S) localized to endosomes/lysosomes, those associated with hypocholesterolemia did not reach this compartment. We conclude that the sorting of PCSK9 to the cell surface and endosomes is required for PCSK9 to fully promote LDLR degradation and that retention in the ER prevents this activity. Mutations that affect this transport can lead to hyper- or hypocholesterolemia.
Similar articles
-
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.J Biol Chem. 2007 Jul 13;282(28):20502-12. doi: 10.1074/jbc.M701634200. Epub 2007 May 10. J Biol Chem. 2007. PMID: 17493938
-
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.J Biol Chem. 2009 Oct 16;284(42):28856-64. doi: 10.1074/jbc.M109.037085. Epub 2009 Jul 27. J Biol Chem. 2009. PMID: 19635789 Free PMC article.
-
Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.Hum Mol Genet. 2012 Mar 15;21(6):1402-9. doi: 10.1093/hmg/ddr578. Epub 2011 Dec 8. Hum Mol Genet. 2012. PMID: 22156580
-
Sorting an LDL receptor with bound PCSK9 to intracellular degradation.Atherosclerosis. 2014 Nov;237(1):76-81. doi: 10.1016/j.atherosclerosis.2014.08.038. Epub 2014 Sep 2. Atherosclerosis. 2014. PMID: 25222343 Review.
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):835-43. doi: 10.1016/j.numecd.2011.06.002. Epub 2011 Sep 23. Nutr Metab Cardiovasc Dis. 2011. PMID: 21943799 Review.
Cited by
-
New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease.Biomedicines. 2022 Apr 22;10(5):970. doi: 10.3390/biomedicines10050970. Biomedicines. 2022. PMID: 35625707 Free PMC article. Review.
-
Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.Biomedicines. 2021 Nov 27;9(12):1783. doi: 10.3390/biomedicines9121783. Biomedicines. 2021. PMID: 34944600 Free PMC article.
-
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.Biochem J. 2009 May 1;419(3):577-84. doi: 10.1042/BJ20082407. Biochem J. 2009. PMID: 19196236 Free PMC article.
-
PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.PLoS One. 2013 Aug 12;8(8):e72113. doi: 10.1371/journal.pone.0072113. eCollection 2013. PLoS One. 2013. PMID: 23951290 Free PMC article.
-
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies.Curr Atheroscler Rep. 2023 Nov;25(11):839-859. doi: 10.1007/s11883-023-01154-7. Epub 2023 Oct 17. Curr Atheroscler Rep. 2023. PMID: 37847331 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous